AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12633783
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg risedronate
Trial: 10709154
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg risedronate
Trial: 30953319
Drug: GLPG1690 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1690 600 mg once daily for 12 weeks
Trial: 30953319
Drug: GLPG1690 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1690 (various doses from 20 mg to 1500 mg, including multiple daily doses of 300-1000 mg)
Trial: 31179008
Drug: GLPG1690 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1690 600 mg
Trial: 27050139
Drug: Intra-articular sprifermin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular sprifermin (300 μg)
Trial: 27050139
Drug: Intra-articular sprifermin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular sprifermin (single and multiple doses)
Trial: 25048494
Drug: Once-daily tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily tacrolimus (extended-release), converted from twice-daily tacrolimus at 1 month post-transplantation
Trial: 26360125
Drug: Twice-daily tacrolimus
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily tacrolimus
Trial: 31993943
Drug: Once-daily tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily tacrolimus
Trial: 22508830
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg plus entinostat 10 mg (EE)
Trial: 22508830
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg plus placebo (EP)
Trial: 20181970
Drug: Lasofoxifene 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasofoxifene 0.5 mg/day
Trial: 20181970
Drug: Lasofoxifene 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasofoxifene 0.25 mg/day
Trial: 15643700
Drug: DTP-PRP-T (Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP-PRP-T (Hib conjugate) vaccine
Trial: 11115824
Drug: Lexipafant (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lexipafant (100 mg/24 hours intravenously for seven days)
Trial: 9531201
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (suture repair of disrupted ligaments within 72 hours, followed by immobilization in a below-the-knee plaster cast for 6 weeks)
Trial: 9531201
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (ankle orthosis for 6 weeks)
Trial: 8010422
Drug: Dorsal penile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsal penile nerve block (DPNB) with additional ventral injection
Trial: 2499490
Drug: Endobronchial glypressin
RxNorm normalized name: Lypressin
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endobronchial glypressin (1 mg)
Trial: 2499490
Drug: Intravenous glypressin
RxNorm normalized name: Lypressin
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glypressin (1 mg)
Trial: 2499490
Drug: Intravenous glypressin
RxNorm normalized name: Lypressin
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glypressin
Trial: 31738448
Drug: Lidocaine 0.5%
RxNorm normalized name: LIDOCAINE 0.5% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 0.5% (5 mL)
Trial: 31738448
Drug: Lidocaine 0.5%
RxNorm normalized name: LIDOCAINE 0.5% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 0.5% (10 mL)
Trial: 24534012
Drug: Dietary insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary insulin load
Trial: 23751748
Drug: Diagnostic protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic protocol consisting of judgment possible site, determining probable etiology, checking and feedbacks on laboratory test in 12 hours, and reassessment and adjustment treatment in 48-72 hours.
Trial: 9043839
Drug: Simvastatin (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (combined 20 mg and 40 mg)
Trial: 3280388
Drug: Charcoal hemoperfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Charcoal hemoperfusion for 5 or 10 hours daily in trial A (75 patients with grade 3 encephalopathy)
Trial: 3280388
Drug: Charcoal hemoperfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Charcoal hemoperfusion for 10 hours daily in trial B (62 patients with grade 4 encephalopathy)
Trial: 3280388
Drug: Etiologic subgroups
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etiologic subgroups (acetaminophen, hepatitis A, hepatitis B, presumed non-A, non-B hepatitis, halothane or drug reaction)
Trial: 30173448
Drug: Huanshao Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huanshao Capsules (HSC) at the dose of 3 capsules tid for 12 weeks
Trial: 22474997
Drug: Wuziyanzong Pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuziyanzong Pills at 6 g bid for 12 weeks
Trial: 25089280
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with partially hydrolyzed guar gum (PHGG) for 10 months
Trial: 25089280
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance therapy (Control group)
Trial: 22681769
Drug: artemether-lumefantrine (AL),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artemether-lumefantrine (AL), 3-day, twice daily oral administration
Trial: 19104169
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion (0.075 microg x kg x h)
Trial: 17879400
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous and oral antioxidants
Trial: 17879400
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of antioxidants
Trial: 11876696
Drug: Chewable CaCO3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewable CaCO3 tablets (750 mg, 1500 mg, 3000 mg)
Trial: 11876696
Drug: Effervescent bicarbonate
RxNorm normalized name: potassium bicarbonate Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent bicarbonate solution
Trial: 11876696
Drug: Swallowable CaCO3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowable CaCO3 tablets
Trial: 2296985
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin A (200,000 IU)
Trial: 153679
Drug: Clofezone (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofezone (1200 mg for the first week, 600 mg for the second week)
Trial: 153679
Drug: Diclofenac (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (150 mg for the first week, 75 mg for the second week)
Trial: 7223751
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of allopurinol tablets (300 mg)
Trial: 7223751
Drug: Cocoa butter
RxNorm normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa butter suppositories (300 mg allopurinol)
Trial: 7223751
Drug: PEG suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG suppositories (300 mg allopurinol)
Trial: 31709115
Drug: Low-dose Edaravone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Edaravone Dexborneol (12.5 mg)
Trial: 31709115
Drug: Medium-dose Edaravone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose Edaravone Dexborneol (37.5 mg)
Trial: 31709115
Drug: High-dose Edaravone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Edaravone Dexborneol (62.5 mg)
Trial: 31709115
Drug: Edaravone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone (30 mg) - Control group
Trial: 28199364
Drug: Low‐Molecular‐Weight Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐Molecular‐Weight Heparin (LMWH) - dalteparin (Fragmin®) 5000 IE once daily
Trial: 25720712
Drug: Strengthened antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strengthened antihypertensive (intravenous antihypertensive drugs controlled at 130‐140 mmHg for 24 h)
Trial: 25720712
Drug: Normal antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal antihypertensive (intravenous antihypertensive drugs controlled at 160‐180 mmHg for 24 h)
Trial: 25720712
Drug: Strengthened antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strengthened antihypertensive
Trial: 25720712
Drug: Normal antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal antihypertensive
Trial: 24088416
Drug: Fermented red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented red ginseng (FRG) capsules
Trial: 22324379
Drug: KW-7158 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-7158 (oral administration)
Trial: 12105831
Drug: Antibiotics (ciprofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (ciprofloxacin and metronidazole, both 500 mg twice daily) + budesonide (9 mg once daily)
Trial: 12105831
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + budesonide (9 mg once daily)
Trial: 12105831
Drug: Antibiotics (ciprofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (ciprofloxacin and metronidazole, both 500 mg twice daily)
Trial: 7782014
Drug: Formalized follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formalized follow-up protocols (e.g. bone scintigraphy, chest X-ray, abdominal ultrasound, mammography, laboratory investigations)
Trial: 113807
Drug: Amitriptyline (AMI)
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline (AMI) 150 mg/day for 6 weeks
Trial: 23611977
Drug: Autologous UCB
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous UCB infusion, 1 year of daily oral vitamin D (2000 IU), and DHA (38 mg/kg) and intensive diabetes management
Trial: 16952492
Drug: 6-drug cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-drug cocktail (flurbiprofen 50 mg, caffeine 100 mg, mephenytoin 100 mg, debrisoquin 10 mg, chlorzoxazone 250 mg, dapsone 100 mg)
Trial: 16952492
Drug: 5-drug cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquin 10 mg, chlorzoxazone 250 mg, dapsone 100 mg)
Trial: 16952492
Drug: flurbiprofen alone
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: flurbiprofen alone (50 mg)
Trial: 15609591
Drug: Combined Acupuncture-Drug
RxNorm normalized name: antibiotics in combination with other drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Acupuncture-Drug Anesthesia (AA)
Trial: 12366880
Drug: Intermittent targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent targeted therapy
Trial: 1867917
Drug: Continuous maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous maintenance therapy
Trial: 9468465
Drug: Antenatal thyrotropin-releasing
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal thyrotropin-releasing hormone (400 microg each at eight-hour intervals, four doses)
Trial: 7876650
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine by jet injector
Trial: 7876650
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine by needle
Trial: 7876650
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine by needle
Trial: 7876650
Drug: Both hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both hepatitis vaccines by needle in separate arms
Trial: 7067925
Drug: Metronidazole 2
RxNorm normalized name: metronidazole 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 2 g single dose
Trial: 389352
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg twice daily for five days
Trial: 30649593
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (100,000 IU single bolus followed by 4,000 IU daily for 16 weeks)
Trial: 29512200
Drug: brodalumab 140
RxNorm normalized name: brodalumab 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brodalumab 140 or 210 mg every 2 weeks (Q2W)
Trial: 20932521
Drug: Cement augmentation
RxNorm normalized name: Cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cement augmentation technique (group A, 40 patients)
Trial: 20932521
Drug: Cement augmentation
RxNorm normalized name: Cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cement augmentation technique (group A)
Trial: 6401442
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine
Trial: 7573998
Drug: Both intravenous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intravenous and epidural clonidine
Trial: 2015917
Drug: Breast conserving
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast conserving treatment
Trial: 24717377
Drug: Choice of
RxNorm normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice of treatment
Trial: 30672067
Drug: IVIG restabilization
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG restabilization with an induction dose of 2 g/kg bodyweight (bw) IgPro10 (Privigen) and maintenance doses of 1 g/kg bw every 3 weeks for up to 13 weeks
Trial: 27399131
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (ticagrelor and apixaban)
Trial: 27399131
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (ticagrelor and apixaban with acetylsalicylic acid)
Trial: 16564798
Drug: Lisinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10 mg daily)
Trial: 12626213
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg daily)
Trial: 20715300
Drug: Mirtazapine (30‐45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (30‐45 mg/day)
Trial: 17383923
Drug: Trigger point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger point injection
Trial: 12416546
Drug: Local chemotherapy
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local chemotherapy with cisplatin-depot (CDDP-D)
Trial: 10451136
Drug: Midazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5 mg x kg(‐1) p.o. 30 min before anesthesia)
Trial: 1522840
Drug: Standard-dose epinephrine
RxNorm normalized name: epinephrine Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose epinephrine (1 mg)
Trial: 2038933
Drug: High-dose epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose epinephrine (5 mg)
Trial: 1315346
Drug: NaF rinse
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NaF rinse (12 mmol/L)
Trial: 1315346
Drug: Two-solution F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-solution F rinse (12 mmol/L)
Trial: 1315346
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (pH 7 remineralizing solution)
Trial: 18815727
Drug: Paracetamol 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1,000 mg - Caffeine 130 mg (PCF)
Trial: 18815727
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 550 mg (NAP)
Trial: 16807444
Drug: Gemcitabine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 300 mg/m(2) administered during 1 h infusion
Trial: 16807444
Drug: Gemcitabine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 300 mg/m(2) administered during 2 h infusion
Trial: 16807444
Drug: Gemcitabine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 300 mg/m(2) administered during 3 h infusion
Trial: 16807444
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m(2) administered during 30 min infusion
Trial: 12669262
Drug: Creatine-pyruvate (Cr(pyr),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine-pyruvate (Cr(pyr), 2 x 3.5 g x d‐1)
Trial: 7960690
Drug: Moderate exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate exercise training (45 min, 3 times weekly for 12 weeks)
Trial: 2884861
Drug: Doxazosin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (mean dosage 6.9 mg, range 1 to 16)
Trial: 2884861
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) (mean dosage 84.6 mg, range 25 to 100)
Trial: 27389084
Drug: Lorcaserin 10
RxNorm normalized name: lorcaserin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin 10 mg twice daily
Trial: 12237201
Drug: Magnesium-lignocaine (20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium-lignocaine (20% magnesium sulphate 500 mg + lignocaine 1% 75 mg)
Trial: 12237201
Drug: Lignocaine alone
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine alone (1% 75 mg)
Trial: 8009327
Drug: Functional restoration
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional restoration treatment at two clinics
Trial: 8009327
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no functional restoration treatment)
Trial: 8009327
Drug: Functional restoration
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional restoration treatment
Trial: 26087107
Drug: Hange-Shashin-To (HST)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hange-Shashin-To (HST) 5.0 g mixed with jelly
Trial: 23618760
Drug: VSL#3 (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VSL#3 (one sachet twice daily for the length of the antibiotics course and for seven days thereafter)
Trial: 23618760
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one sachet twice daily for the length of the antibiotics course and for seven days thereafter)
Trial: 16778264
Drug: Budesonide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (200 mcg qd for children < 11 years old and 400 mcg qd for others)
Trial: 15117980
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m² intravenously (i.v.) day 1 with vitamin B12, folic acid, and dexamethasone
Trial: 15117980
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² i.v. day 1 with dexamethasone
Trial: 9623901
Drug: Bioerodible tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bioerodible tetracycline gel
Trial: 2492674
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 100 micrograms LT4 and 100 micrograms iodide
Trial: 28592515
Drug: Lysine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine (5 or 10 g l-lysine)
Trial: 26010632
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone supplement (100 mg of total isoflavones, n=193)
Trial: 26010632
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone supplement
Trial: 21900836
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 IV, gemcitabine 1500 mg/m2 IV, and bevacizumab 10 mg/kg IV (days 1 and 15 of 28‐day cycles)